<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00202410</url>
  </required_header>
  <id_info>
    <org_study_id>NEU - BCG - 01</org_study_id>
    <nct_id>NCT00202410</nct_id>
  </id_info>
  <brief_title>Efficacy of Anti-Tubercular Vaccination in Multiple Sclerosis</brief_title>
  <official_title>Phase 2-3 Use of Bacille Calmette-Guèrin (BCG) Vaccine in Patients With a First Clinical Demyelinating Episode: a Multicenter, Randomized, Single Blind Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>S. Andrea Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Italian Multiple Sclerosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituto Superiore di Sanità</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>S. Andrea Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The frequency of auto-immune diseases (including multiple sclerosis) is increasing in
      industrialised countries.

      According to an hypothesis which is receiving a wide international credit, this may be due to
      the fact that the populations of these countries are increasingly less exposed to microbes
      further to the improvement of hygienic conditions and to the use of antibiotics.

      If exposure to microbes is lacking, also their regulatory function is missed with a
      consequent possible onset of auto-immune symptoms.

      For this reason, it is deemed that by exposing the immune system of a patient to an ancient
      microbe, being complex and important in man evolution, like the Tuberculosis Mycobacterium,
      it is possible to rebalance the immune system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vaccination with the Tuberculosis Mycobacterium has proved to be effective in the animal
      model of multiple sclerosis, experimental allergic encephalitis.

      In a study of phase I-II our group has demonstrated the safety of this therapy together with
      preliminary evidence.

      The study includes patients with an initial disease (diagnosis supported by paraclinical
      criteria): single clinical poly or mono-symptomatic attack in the 6 months preceding the
      study, MR picture compatible with MS.

      Study design 100 randomized patients (i.e. randomly assigned) to be included either in a
      group of 50 patients undergoing therapy or to a group of 50 patients receiving placebo.

      Patients are followed up with monthly contrast MRI for 6 months. At the end of the six months
      the disease activity in the group of treated patients is benchmarked with the disease
      activity of the group of patients receiving placebo.

      Safety is granted by the extremely wide diffusion of this kind of vaccination worldwide and
      by the previous study in patients affected by multiple sclerosis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of gad-enhancing lesions in T1</measure>
    <time_frame>baseline and 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>number of lesions in T1 and new lesions in T2</measure>
    <time_frame>baseline and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>volume of T2 lesions</measure>
    <time_frame>0 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>volume of T1 lesions (black holes)</measure>
    <time_frame>0 and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>physiologic solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>subcutaneous administration of physiologic solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bacille Calmette-Guèrin (BCG) Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-Tubercular Vaccination</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bacille of Calmette-Guerin</intervention_name>
    <description>A single intracutaneous dose of 0.1 mL freeze-dried BCG (1 mg/mL; Berna Institute, Basel).</description>
    <arm_group_label>Bacille Calmette-Guèrin (BCG) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>subcutaneous administration of physiologic solution</description>
    <arm_group_label>physiologic solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with an initial disease (diagnosis supported by paraclinical criteria):
             single clinical poly or mono-symptomatic attack in the 6 months preceding the study,
             MR picture compatible with MS

        Exclusion Criteria:

          -  Therapy with corticosteroids in the last month

          -  Plasmapheresis, administration of gamma globulins in the last three months

          -  Serious heart, renal, hepatic or haematological dysfunction defined by laboratory
             exams

          -  Evidence of infections

          -  Evidence of tubercular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Salvetti, Professor</last_name>
    <role>Study Director</role>
    <affiliation>S.Andrea Hospital, University of Rome &quot;La Sapienza&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giovanni Ristori, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Roma La Sapienza</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Neurology - University of Rome La Sapienza</name>
      <address>
        <city>Rome</city>
        <state>Roma</state>
        <zip>00100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Ristori G, Buzzi MG, Sabatini U, Giugni E, Bastianello S, Viselli F, Buttinelli C, Ruggieri S, Colonnese C, Pozzilli C, Salvetti M. Use of Bacille Calmette-Guèrin (BCG) in multiple sclerosis. Neurology. 1999 Oct 22;53(7):1588-9.</citation>
    <PMID>10534275</PMID>
  </reference>
  <reference>
    <citation>Salvetti M, Pisani A, Bastianello S, Millefiorini E, Buttinelli C, Pozzilli C. Clinical and MRI assessment of disease activity in patients with multiple sclerosis after influenza vaccination. J Neurol. 1995 Feb;242(3):143-6.</citation>
    <PMID>7751856</PMID>
  </reference>
  <reference>
    <citation>Confavreux C, Suissa S, Saddier P, Bourdès V, Vukusic S; Vaccines in Multiple Sclerosis Study Group. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med. 2001 Feb 1;344(5):319-26.</citation>
    <PMID>11172162</PMID>
  </reference>
  <reference>
    <citation>Rook GA, Ristori G, Salvetti M, Giovannoni G, Thompson EJ, Stanford JL. Bacterial vaccines for the treatment of multiple sclerosis and other autoimmune disorders. Immunol Today. 2000 Oct;21(10):503-8. Review.</citation>
    <PMID>11071529</PMID>
  </reference>
  <reference>
    <citation>Buttinelli C, Salvetti M, Ristori G. Vaccinations and multiple sclerosis. N Engl J Med. 2001 Jun 7;344(23):1794; author reply 1795-6.</citation>
    <PMID>11396455</PMID>
  </reference>
  <reference>
    <citation>O'Riordan JI, Thompson AJ, Kingsley DP, MacManus DG, Kendall BE, Rudge P, McDonald WI, Miller DH. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain. 1998 Mar;121 ( Pt 3):495-503.</citation>
    <PMID>9549525</PMID>
  </reference>
  <reference>
    <citation>Brex PA, O'Riordan JI, Miszkiel KA, Moseley IF, Thompson AJ, Plant GT, Miller DH. Multisequence MRI in clinically isolated syndromes and the early development of MS. Neurology. 1999 Oct 12;53(6):1184-90.</citation>
    <PMID>10522870</PMID>
  </reference>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>May 18, 2011</last_update_submitted>
  <last_update_submitted_qc>May 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Marco Salvetti</name_title>
    <organization>University of Rome &quot;Sapienza&quot;</organization>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Tuberculosis vaccine</keyword>
  <keyword>Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Antitubercular Agents</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 10, 2014</submitted>
    <returned>March 24, 2014</returned>
    <submitted>December 1, 2015</submitted>
    <returned>January 5, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

